About Alkermes plc
https://www.alkermes.comAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally.
CEO
Richard F. Pops
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2000-05-15 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 245
Ratings Snapshot
Rating : A+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:29.11M
Value:$891.27M
BLACKROCK, INC.
Shares:27.97M
Value:$856.51M
VANGUARD GROUP INC
Shares:18.18M
Value:$556.66M
Summary
Showing Top 3 of 469
About Alkermes plc
https://www.alkermes.comAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $394.19M ▲ | $253.51M ▲ | $82.76M ▼ | 21% ▼ | $0.5 ▼ | $108.83M ▼ |
| Q2-2025 | $390.66M ▲ | $248.22M ▲ | $87.1M ▲ | 22.3% ▲ | $0.53 ▲ | $112.66M ▲ |
| Q1-2025 | $306.51M ▼ | $243.52M ▲ | $22.46M ▼ | 7.33% ▼ | $0.14 ▼ | $32.91M ▼ |
| Q4-2024 | $429.99M ▲ | $205.18M ▼ | $146.5M ▲ | 34.07% ▲ | $0.9 ▲ | $181.38M ▲ |
| Q3-2024 | $378.14M | $210.29M | $92.38M | 24.43% | $0.57 | $123.2M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.11B ▲ | $2.33B ▲ | $596.08M ▼ | $1.73B ▲ |
| Q2-2025 | $1.02B ▲ | $2.25B ▲ | $628.23M ▲ | $1.62B ▲ |
| Q1-2025 | $884.02M ▲ | $2.08B ▲ | $570.39M ▼ | $1.51B ▲ |
| Q4-2024 | $751.67M ▼ | $2.06B ▼ | $590.59M ▼ | $1.46B ▲ |
| Q3-2024 | $908.86M | $2.16B | $863.18M | $1.29B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $82.76M ▼ | $101.67M ▼ | $-6.74M ▲ | $315K ▼ | $95.25M ▼ | $84.36M ▼ |
| Q2-2025 | $87.1M ▲ | $150.2M ▲ | $-29.21M ▼ | $405K ▼ | $121.39M ▲ | $137.19M ▲ |
| Q1-2025 | $22.46M ▼ | $98.81M ▼ | $9.1M ▲ | $747K ▲ | $108.66M ▲ | $88.7M ▼ |
| Q4-2024 | $146.5M ▲ | $190.4M ▲ | $-13.88M ▲ | $-281.67M ▼ | $-105.15M ▲ | $180.62M ▲ |
| Q3-2024 | $92.38M | $81.59M | $-109.33M | $-111.11M | $-138.86M | $73.33M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Aristada And Aristada Initio | $100.00M ▲ | $0 ▼ | $100.00M ▲ | $100.00M ▲ |
 L Y B A L V I | $80.00M ▲ | $0 ▼ | $80.00M ▲ | $100.00M ▲ |
 Manufactured Product And Royalty | $0 ▲ | $60.00M ▲ | $0 ▼ | $0 ▲ |
 Product | $310.00M ▲ | $240.00M ▼ | $310.00M ▲ | $320.00M ▲ |
 Vivitrol | $130.00M ▲ | $0 ▼ | $120.00M ▲ | $120.00M ▲ |
CEO
Richard F. Pops
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2000-05-15 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 245
Ratings Snapshot
Rating : A+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:29.11M
Value:$891.27M
BLACKROCK, INC.
Shares:27.97M
Value:$856.51M
VANGUARD GROUP INC
Shares:18.18M
Value:$556.66M
Summary
Showing Top 3 of 469